Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 3Gastrointestinal 2Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Stomach Neoplasms 172Esophageal Neoplasms 161Esophageal Squamous Cell Carcinoma 116Cholangiocarcinoma 77Pancreatic Neoplasms 73Biliary Tract Neoplasms 72Adenocarcinoma Of Esophagus 52Gallbladder Neoplasms 39Colorectal Neoplasms 36Neoplasm Metastasis 30Carcinoma, Non-Small-Cell Lung 28Carcinoma, Hepatocellular 28Neoplasms 27Bile Duct Neoplasms 24Ovarian Neoplasms 19Liver Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 15Colonic Neoplasms 13Peritoneal Neoplasms 12Gastrointestinal Neoplasms 12Anus Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Adenocarcinoma 11Rectal Neoplasms 9Melanoma 9Lung Neoplasms 9Carcinoma, Squamous Cell 9Breast Neoplasms 9Sarcoma 8Hepatoblastoma 8

Interventions

Gemcitabine 4pembrolizumab 3napabucasin 3Irinotecan 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3lenvatinib 2entinostat 2Taxes 2Sunitinib 2Sorafenib 2Paclitaxel 2Leucovorin 2Fluorouracil 2Cisplatin 2Bevacizumab 2pralsetinib 1linifanib 1durvalumab 1Radiofrequency Ablation 1Pemetrexed 1Nivolumab 1Immunotherapy 1Endoscopic Mucosal Resection 1Cobicistat 1Chemoradiotherapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms, Glandular and Epithelial × Cisplatin × Gastrointestinal × Clear all
NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

NCT03535727 2024-12-31

A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
48 enrolled 24 charts
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms, Neoplasms, Glandular and Epithelial, Pancreatic Diseases, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡